ask the EMA oracle [Outliers]

posted by Ohlbe – France, 2011-10-06 18:31 (5026 d 14:38 ago) – Posting: # 7436
Views: 9,514

Dear D. Labes,

❝ A little bit curious for me is the underlined sentence. Taken literally it would not allow to exclude such profiles for the Test formulation :confused:.


My understanding is that this is precisely the idea ! Basically, if no concentration is measured after the reference product, EU regulators are ready to assume that the subject did not swallow the product. The reference formulation is considered to be reliable :-|
If the same situation happens after the test product, they consider that they cannot make the difference between a non-compliant subject and a deficient tablet. They will not take any chance.

Regards
Ohlbe

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
23,430 posts in 4,931 threads, 1,672 registered users;
100 visitors (0 registered, 100 guests [including 43 identified bots]).
Forum time: 09:09 CEST (Europe/Vienna)

It has yet to be proven
that intelligence has any survival value.    Arthur C. Clarke

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5